Tafenoquine in Patients With Mild to Moderate COVID-19

NCT04533347 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID 19 Disease

Interventions

DRUG: Tafenoquine Oral Tablet
DRUG: Placebo

Sponsor

60 Degrees Pharmaceuticals LLC